Eli Lilly and Company

Other

Wayne State University

University of Hawai'i

John E Toth

James E Ray

Herbert A Kirst

William J Ehlhardt

J Jeffry Howbert

Daniel Jon Sall

Michael J Martinelli

Perry C Heath

Eric D Moher

Gerald B Grindey

Jane G Amos

Douglas E Prather

Jason Scott Sawyer

Vinod Francis Patel

Chuan Shih

John E Munroe

Jolie Anne Bastian

Theodore Goodson, Jr

Bryan Hurst Norman

Kumiko Takeuchi

Karen Lynn Lobb

Jefferson Ray McCowan

Richard E Moore

David Lee Varie

Mary Margaret Mader

George B Boder

David W Hoard

Venkatraghavan Vasudevan

Cora Sue Grossman

Vien V Khau

John L Zimmermann

Rima S Al-Awar

John F Worzalla

Subbaraju V Gottumukkala

Todd Johnathan Kohn

Joseph M Pawlak

Naresh K Nayyar

Arindam Chatterjee

The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.

Mixed lineage kinase modulators

Cryptophycin compounds

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of defined compounds of formula (I) as thrombin inhibitors.

Antithrombotic agents

This invention provides certain substituted benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.

Antitumor compositions and methods of treatment

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.

Process and novel intermediates

This invention provides certain substituted 2,3-dihydrobenzofurylsulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.

This invention provides for crystalline hydrochloride C.sub.1 -C.sub.3 alcohol solvate forms of the compound of formula (I): ##STR1## In particular, crystalline hydrochloride ethanol, methanol, and propanol solvates are disclosed.

Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof

This invention provides certain benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier, and processes for preparing the benzenesulfonamide derivatives.

This invention provides for crystalline hydrochloride C.sub.1 -C.sub.3 alcohol solvate forms of the compound of formula (I): ##STR1## In particular, crystalline hydrochloride ethanol, methanol, and propanol solvates are disclosed. Also disclosed are processess for preparing and using the above compounds.

This invention provides certain sulfonamidoquinoxaline derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these sulfonamidoquinoxaline derivatives, in combination with a carrier, diluent or excipient.

This invention provides certain N-phenyl-N'-substituted phenylsulfonylureas compounds, formulations, and a method for treating susceptible neoplasms in mammals using the sulfonylurea compounds.

This invention provides the use of certain indenesulfonamide derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel indenesulfonamide derivatives and their pharmaceutical formulations.

This invention provides certain sulfonimidamide compounds, formulations and method of use of these compounds in treating susceptible neoplasms.

Sulfonimidamides

This invention provides the use of N-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3-dihydrobenzofuran-5-sulfonamid e, and pharmaceutically acceptable salts thereof, in the treatment of susceptible neoplasms in mammals. This invention further provides the novel aforementioned compound and its pharmaceutical formulations.

Growing community of inventors

Indianapolis, IN, United States of America

John E Toth